Pdt Partners, LLC Tcr2 Therapeutics Inc. Transaction History

Pdt Partners, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.86 - $3.75 $107,003 - $215,733	-57,529 Reduced 69.52%	25,225 $45,000
Q2 2022 Aug 15, 2022	SELL	$2.11 - $2.94 $171,294 - $238,675	-81,182 Reduced 49.52%	82,754 $240,000
Q1 2022 May 16, 2022	BUY	$2.4 - $4.71 $11,964 - $23,479	4,985 Added 3.14%	163,936 $452,000
Q4 2021 Feb 14, 2022	BUY	$4.58 - $8.34 $611,576 - $1.11 Million	133,532 Added 525.32%	158,951 $741,000
Q3 2021 Nov 15, 2021	BUY	$8.44 - $18.35 $214,536 - $466,438	25,419 New	25,419 $216,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.